A photo of Michael Jordan.

Member, Division of Bone Marrow Transplantation and Immune Deficiency

Member, Division of Immunobiology

Professor, UC Department of Pediatrics



Board Certified

My Biography & Research

Clinical Interests

Histiocytic disorders: HLH and LCH

Research Interests

Better understanding histiocytic disorders and developing novel therapies for them; regulation of the immune response; immunotherapy of cancer

Academic Affiliation

Professor, UC Department of Pediatrics

Clinical Divisions

Cancer and Blood Diseases, Immune Deficiencies and Histiocytosis, Bone Marrow Transplantation BMT, Leukemia, Hemophagocytic lymphohistiocytosisHLH, Histiocytosis Center, Autoimmune Liver Disease, Rare Lung Diseases

Research Divisions

Bone Marrow Transplantation and Immune Deficiency, Cancer and Blood Diseases, Immunobiology

Blog Posts

NEJM: Emapalumab Clinical Trial Shows Positive Results Against HLH

Rare Diseases

NEJM: Emapalumab Clinical Trial Shows Positive Results Against HLH

Michael B. Jordan, MD5/7/2020

Breakthrough Therapy Improves Life for Children with LRBA Deficiency

Rare Diseases

Breakthrough Therapy Improves Life for Children with LRBA Deficiency

Michael B. Jordan, MD6/28/2019

My Locations

My Education

MD: UT Southwestern, Dallas, TX, 1993.

Residency: Children's Hospital of Dallas, Dallas, TX, 1996.

Fellowship: The Children's Hospital, Denver, CO, 2002.

Certification: American Board of Pediatrics, 1996; Sub-board of Pediatric Heme/Onc, 2002.

My Publications

Daratumumab for the management of autoimmune cytopenias in children and young adults: a case series. Khandelwal, P; Teusink-Cross, A; Kumar, AR; Bleesing, JJ; Mehta, PA; Jordan, MB; Chandra, S; Davies, SM; Marsh, RA. British Journal of Haematology. 2021.

T-cell activation profiles distinguish hemophagocytic lymphohistiocytosis and early sepsis. Marsh, RA; Zoref-Lorenz, A; Owsley, E; Chaturvedi, V; Nguyen, TC; Goldman, JR; Henry, MM; Greenberg, JN; Ladisch, S; Hermiston, ML; et al. Blood. 2021; 137:2337-2346.

Challenges in improving global outcomes for hemophagocytic lymphohistiocytosis. Zoref-Lorenz, A; Jordan, MB. Pediatric Hematology and Oncology. 2021; 38:191-193.

Discrepancies between F-18-FDG PET/CT findings and conventional imaging in Langerhans cell histiocytosis. Ferrell, J; Sharp, S; Kumar, A; Jordan, M; Picarsic, J; Nelson, A. Pediatric Blood and Cancer. 2021; 68.

Experience with a Reduced Toxicity Allogeneic Transplant Regimen for Non-CGD Primary Immune Deficiencies Requiring Myeloablation. Chandra, S; Chandrakasan, S; Dávila Saldaña, BJ; Bleesing, JJ; Jordan, MB; Kumar, AR; Grimley, MS; Krupski, C; Davies, SM; Khandelwal, P; et al. Journal of Clinical Immunology. 2021; 41:89-98.

Possible roads to improve hemophagocytic lymphohistiocytosis outcome. Merli, P; Jordan, MB; Locatelli, F. Blood Advances. 2020; 4:6127-6129.

Multiplexed Functional Assessment of Genetic Variants in CARD11. Meitlis, I; Allenspach, EJ; Bauman, BM; Phan, IQ; Dabbah, G; Schmitt, EG; Camp, ND; Torgerson, TR; Nickerson, DA; Bamshad, MJ; et al. American Journal of Human Genetics. 2020; 107:1029-1043.

A tribute to the life and work of Alexandra (Lisa) H. Filipovich, 1951-2020. Davies, SM; Jordan, MB; Marsh, R. Pediatric Blood and Cancer. 2020; 67.

Emapalumab in Primary Hemophagocytic Lymphohistiocytosis. Reply. Jordan, MB; Locatelli, F. New England Journal of Medicine. 2020; 383:598-599.

CCR5 inhibitor as novel acute graft versus host disease prophylaxis in children and young adults undergoing allogeneic stem cell transplant: results of the phase II study. Khandelwal, P; Fukuda, T; Teusink-Cross, A; Kashuba, AD M; Lane, A; Mehta, PA; Marsh, RA; Jordan, MB; Grimley, MS; Myers, KC; et al. Bone Marrow Transplantation. 2020; 55:1552-1559.